In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novo Nordisk proposes Ablynx takeover for cash bid of €28/share, CVRs; later outbid by Sanofi

Executive Summary

Ablynx NV first announced to the public offers made back in December 2017 by fellow antibody developer Novo Nordisk AS, which initially proposed on December 6th to acquire Ablynx for €26.75 ($31.60; a 39% premium) per share (for an equity value of €1.99bn); the Ablynx board rejected the offer, claiming it undervalued the company. In a revised bid on December 22nd, Novo offered €28.00 per share (a 46% premium) in cash, plus up to €2.50/share in contingent value rights (CVRs; based on the progress of two Ablynx development candidates), for an equity value of €2.3bn ($2.7bn), which Ablynx also vetoed. Industry sources believe a bidding war could ensue with Novo coming back with a higher offer and Gilead, Amgen, and AbbVie also joining the mix as possible suitors.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Includes Earnout
    • Payment Includes Cash
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register